Pigment cell disorders
Conditions
Interventions
None listed
Sponsors
Amsterdam UMC
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients: • Patients with pigment cell disorders: vitiligo, genetic pigment cell disorders (e.g. piebaldism, nevus depigmentosis, segmental hypomelanosis) or pityriasis • Age >=18 • Patient is willing and able to give written informed consent Healthy Donors: • Age >=18 • Patient is willing and able to give written informed consent
Exclusion criteria
Exclusion criteria: Patients: • Hypertrophic scars. • Keloid. • Patients with a history of hypersensitivity or allergy to local anaesthesia. • Patients with haemophilia or other clotting disorders. • Patients not competent to understand what the procedures involves. Healthy Donors: •• People with pigment cell disorders: vitiligo, genetic pigment cell disorders (e.g. piebaldism, nevus depigmentosis, segmental hypomelanosis) or pityriasis • Hypertrophic scars • Keloid • People with a history of hypersensitivity or allergy to local anaesthesia • People with haemophilia or other clotting disorders • People who are competent to understand what the procedures involve
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Aim 1: To identify the key pathologic cells and their function in active or stable nonsegmental vitiligo as compared to pigment cell disorders with low or no autoimmune involvement (segmental vitiligo, genetic pigment disorders, pityriasis), healthy donors or asymptomatic skin of vitiligo patients. Aim 2: To assess whether identified putative pathogenic cells persist in the skin lesions that do not respond (repigment) to treatment, as compared to responding lesions. | — |
Secondary
| Measure | Time frame |
|---|---|
| Not applicable. There are no secundary study parameters and all the study parameters are already mentioned in the primary study parameters. | — |
Countries
Netherlands
Outcome results
None listed